About Shire (NASDAQ:SHPG)
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).
Industry, Sector and Symbol
Trailing P/E Ratio8.97153024911032
Forward P/E Ratio8.27
Sales & Book Value
Annual Sales$15.16 billion
Price / Sales2.50
Cash Flow$16.29 per share
Price / Cash7.74
Book Value$95.20 per share
Price / Book1.32
Net Income$4.27 billion
Return on Equity14.75%
Return on Assets6.88%
Shire (NASDAQ:SHPG) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the NASDAQ under the ticker symbol "SHPG."
How often does Shire pay dividends? What is the dividend yield for Shire?
Shire declared a semiannual dividend on Friday, February 16th. Stockholders of record on Friday, March 9th will be given a dividend of $0.8937 per share on Tuesday, April 24th. This represents a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. This is an increase from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History.
How were Shire's earnings last quarter?
Shire PLC (NASDAQ:SHPG) posted its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, topping the Zacks' consensus estimate of $3.86 by $0.12. The biopharmaceutical company earned $4.14 billion during the quarter. Shire had a return on equity of 14.75% and a net margin of 28.17%. The company's quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the business earned $3.37 earnings per share. View Shire's Earnings History.
When will Shire make its next earnings announcement?
What guidance has Shire issued on next quarter's earnings?
Shire updated its FY18 earnings guidance on Wednesday, February, 14th. The company provided earnings per share guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.02. The company issued revenue guidance of 15.4-15.9 billion, compared to the consensus revenue estimate of $15.47 billion.
Where is Shire's stock going? Where will Shire's stock price be in 2018?
17 equities research analysts have issued twelve-month target prices for Shire's shares. Their forecasts range from $150.00 to $245.00. On average, they anticipate Shire's share price to reach $204.00 in the next twelve months. View Analyst Ratings for Shire.
What are Wall Street analysts saying about Shire stock?
Here are some recent quotes from research analysts about Shire stock:
- 1. Cantor Fitzgerald analysts commented, "Shire reported 4Q17 results and provided its 2018 financial guidance this morning. The report was mixed relative to expectations. Investors that we spoke with were anticipating a strong 4Q17 with no surprises, but hoping for 2018 consensus sales and EPS that would at least bracket consensus (which did not happen)." (2/14/2018)
- 2. According to Zacks Investment Research, "The sales of Mydayis did not meet Shire’s expectation while strong performance of Vyvanse, Cinryze and Elaprase continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past one year. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters." (2/6/2018)
- 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)
Are investors shorting Shire?
Shire saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 2,421,141 shares, a drop of 34.8% from the January 12th total of 3,712,240 shares. Based on an average daily volume of 1,775,924 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.8% of the company's shares are sold short.
Who are some of Shire's key competitors?
Some companies that are related to Shire include Celgene (CELG), GlaxoSmithKline (GSK), AstraZeneca (AZN), Beximco Pharmaceuticals (BXP), Shire (SHP), Teva Pharmaceutical Industries (TEVA), Valeant Pharmaceuticals Intl (VRX), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Patheon (PTHN), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), BTG (BTG), Amicus Therapeutics (FOLD), Emergent Biosolutions (EBS), Horizon Pharma (HZNP), Hikma Pharmaceuticals (HIK) and Opko Health (OPK).
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Flemming Ornskov M.D., Chief Executive Officer, Executive Director (Age 59)
- John Miller, Interim Chief Financial Officer
- Joanne Cordeiro, Chief Human Resource Officer
- Andreas Busch Ph.D., Executive Vice President - Head of Research and Development, Chief Scientific Officer (Age 54)
- Gisele Dion, Chief Accounting Officer, Corporate Controller (Age 51)
- William Mordan, General Counsel, Company Secretary (Age 47)
- Howard Mayer M.D., Chief Medical Officer
- Perry Sternberg, Head - U.S. Commercial (Age 48)
- Kim Stratton, Head - International Commercial (Age 56)
- Philip J. Vickers, Head - Research and Development (Age 56)
Who owns Shire stock?
Shire's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Boston Partners (0.78%), The Manufacturers Life Insurance Company (0.61%), Maverick Capital Ltd. (0.55%), BlackRock Inc. (0.35%), Rockefeller Financial Services Inc. (0.19%) and ING Groep NV (0.17%). View Institutional Ownership Trends for Shire.
Who sold Shire stock? Who is selling Shire stock?
Shire's stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Maverick Capital Ltd., Jennison Associates LLC, Millennium Management LLC, Deutsche Bank AG, BlackRock Inc., Capital Fund Management S.A. and York Capital Management Global Advisors LLC. View Insider Buying and Selling for Shire.
Who bought Shire stock? Who is buying Shire stock?
Shire's stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, ING Groep NV, FNY Partners Fund LP, Brandywine Global Investment Management LLC, Snow Capital Management LP, Bank of Montreal Can, Delek Group Ltd. and OLD Mission Capital LLC. View Insider Buying and Selling for Shire.
How do I buy Shire stock?
Shares of Shire can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Shire's stock price today?
One share of Shire stock can currently be purchased for approximately $126.05.
How big of a company is Shire?
Shire has a market capitalization of $38.11 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $14.05 on an earnings per share basis. Shire employs 23,906 workers across the globe.
How can I contact Shire?
Shire's mailing address is 5 Riverwalk Citywest Business Campus, Dublin L2, D24. The biopharmaceutical company can be reached via phone at 353-1429-7700 or via email at [email protected]
MarketBeat Community Rating for Shire (SHPG)MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shire (NASDAQ:SHPG) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.71||2.57||2.67||2.70|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$204.00||$212.18||$212.18||$220.91|
|Price Target Upside: ||61.05% upside||34.90% upside||51.53% upside||51.78% upside|
Shire (NASDAQ:SHPG) Consensus Price Target History
Shire (NASDAQ:SHPG) Analyst Ratings History
(Data available from 2/22/2016 forward)
Shire (NASDAQ:SHPG) Earnings History and Estimates Chart
Shire (NASDAQ SHPG) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2018|| || || || || || || || |
|5/2/2017||Q1 17||$3.22||$3.63||$3.57 billion||View||Listen|
|2/16/2017||Q416||$3.24||$3.37||$3.78 billion||$3.81 billion||View||N/A|
|11/1/2016||Q316||$3.21||$3.17||$3.57 billion||$3.45 billion||View||N/A|
|8/2/2016||Q216||$3.03||$3.38||$2.28 billion||$2.43 million||View||N/A|
|4/29/2016||Q1||$3.05||$3.19||$1.71 billion||$1.71 billion||View||Listen|
|2/11/2016||Q415||$2.89||$2.97||$1.69 million||$1.72 billion||View||Listen|
|10/23/2015||Q315||$2.87||$3.24||$1.63 billion||$1.58 billion||View||Listen|
|7/23/2015||Q215||$2.81||$2.63||$1.59 billion||$1.56 billion||View||Listen|
|4/30/2015||Q115||$2.56||$2.84||$1.47 billion||$1.49 billion||View||N/A|
|2/12/2015||Q115||$2.68||$2.63||$1.53 billion||$1.58 billion||View||N/A|
|10/24/2014||Q314||$2.47||$2.93||$1.46 billion||$1.55 billion||View||Listen|
|7/18/2014||Q214||$2.45||$2.67||$1.45 billion||$1.50 billion||View||N/A|
|5/1/2014||Q114||$2.22||$2.36||$1.38 billion||$1.35 billion||View||N/A|
|2/13/2014||Q413||$2.02||$2.26||$1.28 billion||$1.33 billion||View||N/A|
|10/24/2013||Q213||$1.65||$1.77||$1.23 billion||$1.24 billion||View||N/A|
|7/25/2013||$1.60||$1.79||$1.21 billion||$1.28 billion||View||N/A|
|5/2/2013||Q113||$1.56||$1.63||$1.21 billion||$1.16 billion||View||N/A|
|2/14/2013||Q412||$1.58||$1.58||$1.20 billion||$1.20 billion||View||N/A|
Shire (NASDAQ:SHPG) Earnings Estimates
2018 EPS Consensus Estimate: $15.73
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Shire (NASDAQ:SHPG) Dividend Information
|Payout Ratio:||6.55% (Trailing 12 Months of Earnings) |
6.04% (Based on This Year's Estimates)
5.43% (Based on Next Year's Estimates)
Shire (NASDAQ:SHPG) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Shire (NASDAQ SHPG)
No insider trades for this company have been tracked by MarketBeat.com
Shire (NASDAQ SHPG) News Headlines
Shire (NASDAQ:SHPG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Shire (NASDAQ:SHPG) Income Statement, Balance Sheet and Cash Flow Statement
Shire (NASDAQ SHPG) Stock Chart for Thursday, February, 22, 2018